The Swedish Medical Products Agency and the Regional Ethics Committee
have approved the initiation of a clinical trial for a completely new
form of neuroendocrine cancer treatment that uses an oncolytic virus.
The virus owes its development to donations from thousands of people all
over the world. Professor Magnus Essand and researchers Justyna Leja-Jarblad and Kjell
Öberg at Uppsala University have been developing a completely new
treatment for neuroendocrine tumors. The treatment consists of an oncolytic virus which is remarkably effective at destroying neuroendocrine tumors. Donations from thousands of people, including a large gift of two
million Swiss francs from the late businessman Vince Hamilton, has
allowed the Oncolytic Virus Fund to collect enough money to enable
Magnus Essand and his research group to start clinical studies. These
will be the first clinical studies in the world on a genetically
modified virus
which specifically attacks neuroendocrine tumours. The virus treatment
has been named AdVince in recognition of Vince Hamilton's commitment to
and strong support for this research. The Swedish Medical Products Agency and the Regional Ethical Review Board in Uppsala recently gave the OK to start treating patients.
There are many requirements which must be fulfilled in order to carry
out clinical testing on humans. From when the AdVince virus treatment
was first produced, it has taken two years to obtain the go-ahead.
The treatment
will be carried out at the teaching hospital Akademiska sjukhuset and
will be led by physician Kjell Öberg, professor emeritus of oncological
endocrinology at Uppsala University.
No comments:
Post a Comment